CRL · NYSE · CIK 0001100682

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 27, 2025) it reported revenue of $4.0B and net income of -$144.3M, according to its XBRL data on EDGAR. Its EDGAR record lists 59 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$4.0B
Net income, FY2025
-$144.3M
Form 4 filings on record, past 12 months
59

Company overview

Legal name (as filed)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Ticker
CRL
SEC Central Index Key (CIK)
0001100682
Business address
WILMINGTON, MA
State or country of incorporation
—
Fiscal year ends
December 27
SEC filer category
Large accelerated filer
Position in SEC ticker list
#660 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$3.5BFY2021$4.0BFY2022$4.1BFY2023$4.0BFY2024$4.0BFY2025
Net income
$391.0MFY2021$486.2MFY2022$474.6MFY2023$22.2MFY2024-$144.3MFY2025
CRL annual results
ItemFY2021
ended Dec 25, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 30, 2023
FY2024
ended Dec 28, 2024
FY2025
ended Dec 27, 2025
Revenue$3.5B$4.0B$4.1B$4.0B$4.0B
Net income$391.0M$486.2M$474.6M$22.2M-$144.3M
Diluted EPS$7.60$9.48$9.22$0.20-$2.91
Total assets$7.0B$7.6B$8.2B$7.5B$7.1B
Cash and equivalents$241.2M$233.9M$276.8M$194.6M$213.8M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

CRL latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 18, 202610-KAnnual report· period Dec 27, 2025Document · Index
Aug 5, 202610-QQuarterly report· period Jun 27, 2026Document · Index
Sep 24, 20268-KRegulation FD disclosure· period Sep 24, 2026Document · Index
Mar 31, 2026DEF 14ADefinitive proxy statement· period May 5, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about CHARLES RIVER LABORATORIES INTERNATIONAL, INC., by form type:

4 ×21144 ×138-K ×2SCHEDULE 13G/A ×2SCHEDULE 13G ×110-Q ×1
CRL recent filings
FiledFormWhat it isOriginal
Oct 26, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 22, 2026Document · Index
Oct 23, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 21, 2026Document · Index
Oct 22, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 21, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 5, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 24, 20268-KRegulation FD disclosure· period Sep 24, 2026Document · Index
Sep 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 27, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 25, 2026Document · Index
Aug 25, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 20, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 19, 2026Document · Index
Aug 20, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 19, 2026Document · Index
Aug 20, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026Document · Index
Aug 19, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 18, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026Document · Index
Aug 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026Document · Index
Aug 13, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 11, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 11, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 10, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026Document · Index
Aug 10, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026Document · Index
Aug 6, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 5, 2026Document · Index
Aug 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 5, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 5, 202610-QQuarterly report· period Jun 27, 2026Document · Index
Aug 5, 20268-KResults of operations· period Aug 5, 2026Document · Index
Jul 1, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 29, 2026Document · Index
Jun 29, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 5, 2026Document · Index
Jun 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 5, 2026Document · Index
Jun 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 5, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period May 29, 2026Document · Index

Insider filing activity

59 Form 4 filings appear in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Services-Commercial Physical & Biological Research

All 8 companies in Services-Commercial Physical & Biological Research· Companies headquartered in Massachusetts

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001100682 and XBRL company facts. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.